''Next-generation TIL therapies aim to overcome suppressive barriers encountered by TIL to broaden and deepen responses in difficult to treat solid tumors, particularly in epithelial cancers. New approaches aim to enrich for less differentiated and more stem-like TIL, increase the frequency of tumor reactive cells, downregulate expression of inhibitory receptors, and express tethered cytokines to increase function and persistence.'' https://www.immuno-oncologysummit.com/T-Cell
Market Data 
Markets 
